RT Journal Article
T1 A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression
A1 Ribelles, Nuria
A1 López-Siles, J
A1 Sánchez-Muñoz, Alfonso
A1 Sánchez, E
A1 González, E
A1 Sánchez, MJ
A1 Carabantes, F
A1 Sánchez- Rovira, P
A1 Márquez, A
A1 Dueñas, R
A1 Sevilla, I
A1 Alba-Conejo, Emilio
K1 Cáncer - Investigación
AB Capecitabine is a drug that requires the consecutive action of three enzymes: carboxylesterase 2 (CES 2), cytidine deaminase(CDD), and thymidine phosphorylase (TP) for transformation into 5-fluorouracil (5FU). The metabolism of 5FU requires the activity of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) among other enzymes. The present study prospectively examined the possible relationship between the toxicity and efficacy of capecitabine and 14 different polymorphisms in CES 2, CDD, TS and DPD. Between 2003 and 2005, a total of 136 patients with advanced breast or colorectal cancer treated with capecitabine were prospectively enrolled. The presence of two polymorphisms (CDD 943insC and CES 2 Exon3 6046 G/A) were associated with a non-statistically significant higher incidence of grade 3 hand-foot syndrome (HFS) (p=0.07) and grade 3-4 diarrhoea (p=0.09), respectively. Patients heterozygous or homozygous for the polymorphism CES 2 5’UTR 823 C/G exhibited a significantly greater response rate to capecitabine, and time to progression of disease (59%, 8.7 months) than patients with the wild type gene sequence (32%, p=0.015; 5.3 months, p=0.014). For the first time, an association between a polymorphism in the CES2 gene and the efficacy of capecitabine has been described, providing preliminary evidence of its predictive and prognostic value.
PB Bentham Science Publishers Ltd
YR 2008
FD 2008
LK https://hdl.handle.net/10630/29769
UL https://hdl.handle.net/10630/29769
LA eng
NO Ribelles N, López-Siles J, Sánchez A, González E, Sánchez MJ, Carabantes F, Sánchez-Rovira P, Márquez A, Dueñas R, Sevilla I, Alba E. A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Curr Drug Metab. 2008 May;9(4):336-43. doi: 10.2174/138920008784220646. PMID: 18473752.
NO Este artículo ha sido publicado en la revista Current Drug MetabolismEsta versión tiene Licencia Creative Commons CC-BY-NC-ND  Le remito pdf recibido de mi solicitud a la revista del postprint, y que me han enviado por correo electrónico con permiso para su depósito.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 19 ene 2026